Revumenib (Cat No.:I015478) is a potent, selective small-molecule inhibitor of the menin–KMT2A (MLL) interaction, a critical driver in leukemias with KMT2A rearrangements or NPM1 mutations. By disrupting this protein–protein interaction, revumenib reactivates differentiation pathways and suppresses leukemogenic transcriptional programs. It has demonstrated strong clinical activity in relapsed or refractory acute leukemias, earning FDA Breakthrough Therapy Designation. Revumenib represents a first-in-class targeted therapy, offering hope for patients with high-risk leukemias and serving as a valuable tool in epigenetic and hematologic cancer research.